La vendita allo scoperto per Korro Bio dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Korro Bio. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Korro Bio (NASDAQ:KRRO) Azioni, Report sulle vendite allo scoperto

KORRO BIO INC

Korro Bio

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Korro Bio Inc

CSX's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NYSE">CSX</a>) short percent of float has fallen 7.32% since its last report. The company recently reported that it has 28.55 million shares sold short, which is 1.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>CSX Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747069221_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CSX has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing CSX's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, CSX's peer group average for short interest as a percentage of float is 9.37%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is the Market Bullish or Bearish on CSX?

Goldman Sachs analyst Michael Ng maintains Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) with a Buy and lowers the price target from $5.6 to $4.8.

News

Price Target

Analyst Ratings

BLND

Goldman Sachs Maintains Buy on Blend Labs, Lowers Price Target to $4.8

<a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45333766/ethereum-dogecoin-and-other-altcoins-may-erase-4-years-suffering-in-just-months-says-michael-van-de-poppe-amid-historic-bullish-divergence">Altcoins are surging</a> as Bitcoin dominance pulls back, suggesting a renewed flow of capital into Ethereum and the broader altcoin market. Celebrity interest is also heating up, adding fuel to the narrative.
What Happened: Six-time NBA champion Scottie Pippen joined the crypto conversation with a <a href="https://x.com/ScottiePippen/status/1921317743774593468">post</a> on X, declaring "altcoin season is here." 
He highlighted his focus on Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>), Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) and Mog Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MOG</a>) and asked Crypto Twitter what else they&#8217;re bullish on.
Pippen's tweet came just as Bitcoin dominance slipped from 64% to 61.5%, marking a 0.8% decline in a single day. 
According to DamiDefi, this drop <a href="https://x.com/DamiDefi/status/1921928635637969101">reflects</a> a rotation of liquidity toward altcoins, especially Ethereum and altcoins.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> dominance goes crashing as liquidity flows into <a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> and altcoins <a href="https://t.co/T3xt5bab41">pic.twitter.com/T3xt5bab41</a>
&mdash; Dami-Defi (@DamiDefi) <a href="https://twitter.com/DamiDefi/status/1921928635637969101?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Echoing this sentiment, analyst Michael van de Poppe <a href="https://x.com/CryptoMichNL/status/1921920545811259552">pointed</a> to a bearish divergence on the Bitcoin dominance chart, calling it a sign of the altcoin bear market ending. 
Another trader, Niels, <a href="https://x.com/Web3Niels/status/1921913680553238959">sees</a> a BTC dominance drop below 63% pushed altcoins "massively outperforming." 
He pointed out that Ethereum is up 45%, Solana spiked 30%, while many others surged 80%-100%. He believes a macro risk-on environment is reinforcing the altcoin breakout, with momentum clearly shifting in their favor.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45351445/xrp-skyrockets-10-what-is-going-on">XRP Skyrockets 10%: What Is Going On?</a>
Why It Matters: As altcoins gain strength, traders are adjusting their strategies. 
Analyst Miles Deutscher said in his latest <a href="https://www.youtube.com/watch?v=5NbIK4uCu6M">podcast</a> that the trend is clear: &#8220;Long strong alts on pullbacks until the trend has shifted, whilst they&#8217;re still above key high time frame levels.&#8221;
He pegs Bitcoin at $100,000 and Ethereum at $2,000 as crucial levels. 
As long as they remain above these thresholds, Deutscher stays bullish on the further upside. 
Still, he cautions against confusing short-term opportunities with long-term investments:
"I think it&#8217;s a big mistake right now to start loading into or buying or FOMOing into long-term spot just because the market&#8217;s moved," he cautioned, suggesting traders should "treat these shorter-term entries as trades" while maintaining separate strategies for long-term holdings.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45348013/dogecoin-jumps-4-can-doge-hit-1-soon">Dogecoin Jumps 4%: Can DOGE Hit $1 Soon?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$DOGE

$ETH

$MOG

$SHIB

$SOL

$XRP

Scottie Pippen Declares 'Altcoin Season' As Ethereum, XRP, Dogecoin, Shiba Inu Rally

For many Americans approaching retirement, the idea of claiming Social Security benefits at age 62 is tempting. It offers early access to a steady stream of income and can bring a sense of security during uncertain times. But financial expert Suze Orman says this move is often a costly mistake.
In a recent episode of her "<a href="https://omny.fm/shows/suze-ormans-women-and-money/suze-school-the-actions-you-need-to-take-now-with-your-money">Women &amp; Money</a>" podcast, Orman pulled no punches: "Taking your Social Security payments at 62 is wrong." Here's what she means — and why it may be worth waiting.
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<h2 class="wp-block-heading">Claiming Early Comes at a Cost</h2>
While age 62 is the earliest point you can claim <a href="https://www.benzinga.com/personal-finance/25/04/45110258/the-2026-social-security-cola-could-be-the-biggest-in-years-but-inflation-could-still-outpace-your-benefits">Social Security benefits</a>, doing so permanently reduces your monthly payments. Orman reminds listeners that 62 is usually five years before full retirement age, which is between 66 and 67, depending on your birth year.
That early start results in up to a 30% reduction in your monthly benefit — for life. "You are taking a serious hit on it, but that makes you feel more secure," she said. While the idea of receiving money sooner may feel like a safe move, Orman believes many people are letting fear dictate their financial decisions.&nbsp;
<h2 class="wp-block-heading">Who Benefits When You Claim Early?</h2>
Orman argues that <a href="https://www.benzinga.com/25/05/45265236/80000-more-americans-filed-for-social-security-in-march-compared-with-last-year-whats-driving-this-surge">claiming early</a> often benefits the system more than the retiree. "The more of you that take it at 62, the less they have to pay you later on," she said. In other words, starting benefits early helps save money for Social Security, but may cost retirees tens of thousands of dollars over time.
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
With concerns about the future of Social Security funding and the state of staffing with offices being shut down, some Americans are rushing to claim benefits out of fear the program will run out or face serious disruptions. But Orman says this is the wrong approach.&nbsp;
"That doesn't mean Social Security is going to collapse," she stated.
<h2 class="wp-block-heading">When Taking Benefits Early Might Make Sense</h2>
Orman acknowledges that there are valid reasons to claim Social Security at 62. If you&#8217;re in poor health or have a terminal illness, taking benefits early may be practical. But in most cases, she says waiting is the better option — especially for married couples.
"Most of the time it absolutely makes no sense at all taking Social Security before your full retirement age," she said. "And I will still say in most cases if you can wait till you are 70 and it makes sense to do so…especially if you are married."
See Also: <a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a>&nbsp;
<h2 class="wp-block-heading">Take Time To Create a Plan</h2>
Rather than making a quick decision based on fear or uncertainty, Orman urges listeners to plan carefully. The key, she says, is figuring out both the best and worst times for you to claim benefits — not just emotionally, but financially.
"Take action with your Social Security," Orman said. That means understanding how timing impacts your <a href="https://www.benzinga.com/personal-finance/25/03/44424162/its-a-really-really-bad-idea-suze-orman-warns-58-year-old-against-using-a-401k-to-buy-a-lifetime">lifetime income</a> and considering your health, marital status, and overall retirement plan.
Bottom line: If you're nearing retirement, it may be worth thinking twice before taking Social Security at 62. A little patience — and planning — can pay off in the long run.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Suze Orman: 'Taking your Social Security Payments At 62 Is Wrong' - Here's Why

WIIM

FOXA

Fox shares are trading higher after the company reported Q3 financial results and beat its adjusted EPS and revenue estimate.

ABNB

EXPE

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

MMYT

NCLH

PLAY

WYNN

Shares of travel and leisure stocks are trading higher after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could reduce economic uncertainty that has been clouding travel and spending outlook.

Wells Fargo analyst Richard Garchitorena maintains Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) with a Equal-Weight and raises the price target from $28 to $35.

Wells Fargo Maintains Equal-Weight on Mosaic, Raises Price Target to $35

Wells Fargo analyst Richard Garchitorena maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Equal-Weight and raises the price target from $56 to $59.

Wells Fargo Maintains Equal-Weight on Nutrien, Raises Price Target to $59

Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares are trading higher Monday after the U.S. and China agreed to a temporary reduction in most tariffs on <a href="https://www.benzinga.com//node/45352452">each other&#8217;s goods</a>.
What To Know: According to <a href="https://www.npr.org/2025/05/12/nx-s1-5395027/us-china-tariffs-deal-trade-war-beijing-washington">NPR</a>, the deal will drop U.S. tariffs on Chinese goods from 145% to 30% and Chinese duties on U.S. imports from 125% to 10% for a three-month period.
On the U.S. side, the talks were led by Trade Representative Jamieson Greer and Treasury Secretary Scott Bessent, while Vice Premier He Lifeng led the discussions for China.
Bessent said at a press conference that, &#8220;We concluded that we have shared interests, and we both have an interest in balanced trade.&#8221; In addition, Greer stated that there is a &#8220;positive path forward&#8221; on the two countries working to combat fentanyl smuggling.
The updated U.S. tariff levels include a base 10% tariff on all imports, along with an additional 20% tariff introduced earlier this year by President Donald Trump in response to allegations that China is producing chemicals linked to fentanyl.
The U.S. is reportedly now in talks with China to increase its purchases of American goods.
Intel stock may be trading higher as a reduction in tariffs could alleviate some supply chain concerns and improve macro sentiment as well as demand visibility. Other chip stocks, including Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), are also trading higher following the news.
Notably, sales from China accounted for about 30% of Intel&#8217;s <a href="https://seekingalpha.com/news/4432161-intel-faces-potentially-significant-impact-from-chinas-import-tariffs-wells-fargo">revenue in 2024.</a>
See Also: <a href="https://www.benzinga.com/25/05/45353407/ramit-sethi-identifies-two-key-traits-of-people-who-are-growing-their-finances-you-think-in-percentages-and-strategy">Ramit Sethi Identifies Two Key Traits Of People Who Are Growing Their Finances: &#8216;You Think In Percentages And Strategy&#8217;</a>
INTC Price Action: At the time of writing, Intel shares are trading 3.91% higher at $22.25, according to data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro</a>.
Image: via Shutterstock

Movers

INTC

Intel Stock Is Rising Monday: What's Going On?

Goldman Sachs analyst Gabriela Borges maintains AvePoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVPT#NASDAQ">AVPT</a>) with a Neutral and raises the price target from $15 to $17.

AVPT

Goldman Sachs Maintains Neutral on AvePoint, Raises Price Target to $17

Goldman Sachs analyst Mark Delaney maintains Aurora Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) with a Neutral and raises the price target from $6 to $7.

Goldman Sachs Maintains Neutral on Aurora Innovation, Raises Price Target to $7

United Parks &amp; Resorts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) on Monday reported worse-than-expected first-quarter <a href="https://www.benzinga.com/pressreleases/25/05/n45343015/united-parks-resorts-inc-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">2025 results</a>.
The company reported a loss per share of 29 cents, missing the analyst consensus estimate of 21 cents loss. Quarterly sales stood at $286.9 million (down 3.5% year-over-year), missed the analyst view of $294 million.
Total revenue per capita fell 1.8% to $84.62; admissions dropped 4.2% to $46.04, while in-park spending rose 1.1% to a record $38.58.
Also Read: <a href="https://www.benzinga.com//node/45293256">Disney Stock &#8216;Resilient&#8217; In Uncertain Economy As Raised Guidance Signals Confidence</a>
Attendance declined 1.7% year-over-year to 3.4 million, down by about 59,000 guests from the 2024 quarter.
The company repurchased 100,000 shares for $4.6 million and aided 205 wild animals, bringing its total rescued to over 42,000.
Adjusted EBITDA fell 14.8% year-over-year to $67.4 million, down $11.7 million year-over-year.
United Parks exited the quarter with cash and equivalents worth $75.665 million, lower than $115.893 million a year ago.
Total long-term debt (including current maturities) contracted to $2.259 billion from $2.263 billion in the year-ago period.
United Parks &amp; Resorts Inc. Chief Executive Officer Marc Swanson said, &#8220;We are pleased to report another quarter of strong financial results.&#8221; He noted that first-quarter performance was negatively affected by the timing shift of Easter and Spring Break holidays into the second quarter this year, impacting admissions and in-park spending per capita due to the shift in peak operating days.
Swanson also cited timing-related expenses, adding, &#8220;First-quarter results were also impacted by certain timing related impacts that resulted in over five million dollars more of certain expenses being recorded in the first quarter of 2025 compared to the first quarter of 2024. We are also pleased to report that April 2025 attendance was up 8.1% compared to April 2024.&#8221;
He added that 2025 bookings for Discovery Cove, group bookings, and international ticket sales are all tracking ahead of 2024. &#8220;With approximately 75% of our historical attendance and revenue opportunity still ahead of us as of April 30, 2025, we continue to expect new records in revenue and Adjusted EBITDA in 2025.&#8221;
Price Action: PRKS shares are trading higher by 2.08% to $48.16 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45325816">Unfavorable Sports Outcomes Have Negatively Affected DraftKings&#8217; Outlook: Analyst</a></li>
</ul>
Image by Kamira via Shutterstock

Earnings

Equities

Guidance

PRKS

Holiday Timing Impacts United Parks' Q1 Performance

Aurinia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUPH#NASDAQ">AUPH</a>) reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 10 cents</a>.
The biopharma company reported fourth-quarter sales of $62.47 million, up 24% year over year, almost in line with the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45342443/aurinia-pharmaceuticals-reports-financial-results-for-the-three-months-ended-march-31-2025" rel="noreferrer noopener">consensus of $61.54 million</a>.
<ul class="wp-block-list">
<li>Sales from the LUPKYNIS drug for lupus nephritis jumped 25% year over year to $60 million.</li>
<li>License, collaboration, and royalty revenue, which includes manufacturing services revenue from Aurinia&#8217;s collaboration partner, Otsuka, was $2.5 million, up 14%.</li>
</ul>
The company reported an operating income of $21.85 million compared to a loss of $13.25 million a year ago.
Aurinia reported a net income of $23.34 million, better than the loss of $10.75 million a year ago.
Aurinia CEO Peter Greenleaf noted that the company&#8217;s commercial organization is focused on educating rheumatologists about the benefits of initiating the drug LUPKYNIS earlier in the treatment paradigm.
Guidance:&nbsp;Aurinia reaffirms <a href="https://www.benzinga.com/general/biotech/25/02/44019996/autoimmune-disease-focused-aurinia-pharmaceuticals-reports-quarterly-profit-revenue-outlook-below-expectations" target="_blank" rel="noreferrer noopener">fiscal 2025 revenue guidance</a> of $250 million-$260 million versus the consensus of $257.87 million.
Price Action: Aurinia stock is up 2.29% at $8.18 at the last check On Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45352770/nrg-surges-as-q1-crushes-forecasts-and-ls-power-deal-supercharges-long-term-outlook" target="_blank" rel="noreferrer noopener">NRG Energy Surges As Q1 Crushes Forecasts, LS Power Deal Supercharges Long-Term Outlook</a></li>
</ul>

Biotech

Health Care

General

AUPH

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

Wells Fargo analyst Steven Cahall maintains Stagwell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) with a Overweight and lowers the price target from $9 to $8.

STGW

Wells Fargo Maintains Overweight on Stagwell, Lowers Price Target to $8

Goldman Sachs analyst Will Nance maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Buy and raises the price target from $45 to $58.

AFRM

Goldman Sachs Maintains Buy on Affirm Holdings, Raises Price Target to $58

COLM

CPRI

CROX

DECK

LULU

SHOO

Shares of apparel stocks are trading higher after the US and China agreed to a temporary reduction in most tariffs on each other's goods. A reduction in tariffs could alleviate supply chain uncertainty and macroeconomic uncertainty and help boost consumer sentiment.

Wells Fargo analyst Steven Cahall maintains Gray Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTN#NYSE">GTN</a>) with a Equal-Weight and raises the price target from $4 to $4.5.

Wells Fargo Maintains Equal-Weight on Gray Media, Raises Price Target to $4.5

The antitrust trial from the Federal Trade Commission against Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has <a href="https://www.benzinga.com/general/social-media/25/04/44799581/no-expiration-date-on-metas-antitrust-case-says-former-ftc-chair-ahead-of-trial">centered on the company's acquisitions</a> of Instagram and WhatsApp.
The FTC is accusing META of using its power to acquire smaller companies through a<a href="https://www.benzinga.com/25/04/44821791/meta-platforms-used-buy-or-bury-strategy-to-monopolize-social-media-ftc-says"> "buy or bury" strategy.</a>
The trial has revealed that Meta <a href="https://www.benzinga.com/25/04/44832468/snapchat-rejection-resurfaces-as-mark-zuckerberg-defends-meta-in-ftc-trial-and-the-tech-mogul-still-thinks-he-cou">attempted to buy</a> Snapchat and once considered spinning off Instagram on its own, an item that will now be forced on the company if the FTC wins its case.
New Twist: According to a new report, Meta platforms contacted a known critic ahead of the trial.
The New York Post <a href="https://nypost.com/2025/05/12/business/meta-nudged-big-tech-critic-media-research-center-for-help-on-eve-of-ftc-trial-sources/">reported</a> that Meta attempted a last-ditch effort to win favor ahead of the antitrust trial, which began April 14.
According to the report, Meta called the right-leaning watchdog, Media Research Center, in early April ahead of the trial. The Media Research Center is known for taking on big technology companies like Meta Platforms and often calling out companies for censorship and political bias.
A Meta official spoke to MRC executive Dan Schneider about the FTC trial and highlighted Meta's plan to ditch its fact-checking processes for a<a href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression"> "community notes" style </a>similar to the one used by X. The company's past fact-checking methods were often the subject of criticism and censorship accusations by Republicans.
Schneider told the New York Post that he believes the phone call was an attempt to get him "to do something" to win favor with conservatives.
"On the eve of this trial that could have severe ramifications for Meta, (the company official) was throwing a ‘hail Mary' Pass to see if one of its chief critics would run cover for them in some way," Schneider said.
He added that he was not asked directly to do something for Meta. "I think it's clearly accurate that they were hoping I was going to do something."
Schneider said the Meta official may have referenced a settlement before the trial by suggesting the FTC could get a deal "not at trial, but with something beforehand."
Read Also: <a href="https://www.benzinga.com/news/earnings/25/04/45117948/meta-q1-earnings-eps-beat-revenue-up-16-ai-approaches-1-billion-monthly-actives-capital-expenditures-forecast-raised">Meta Q1 Earnings: EPS Beat, Revenue Up 16%, AI Approaches 1 Billion Monthly Actives, Capital Expenditures Forecast Raised</a>
Why It's Important: While Meta declined to comment to the New York Post, Schneider&#8217;s confirmation of the phone call could indicate the social media company&#8217;s efforts to avoid the antitrust trial.
The NY Post story said the MRC previously published several studies on Big Tech censorship, including several that portrayed Meta negatively.
Meta CEO Mark Zuckerberg <a href="https://www.benzinga.com/news/24/12/42454227/months-after-trump-threatened-to-put-mark-zuckerberg-in-prison-meta-ceo-donates-1m-to-president-elects-inaugural-event">announced a $1 million</a> donation to Donald Trump's inauguration, which he attended and also took part in meetings at Mar-a-Lago.
After a previous tense relationship that included Trump threatening to put Zuckerberg in jail, the Meta CEO has appeared to be trying to make nice with the president and conservatives who are upset at past company policies.
The donations, support for Trump, and calls to the MRC were not enough to prevent the antitrust trial from starting.
A Wall Street Journal report also noted that Zuckerberg tried to settle the case before trial, offering $450 million and eventually raising the offer to $1 billion. The FTC has demanded $30 billion in the case. The report says FTC chairman Andrew Ferguson said he would not settle the case for less than $18 billion.
As the antitrust trial continues, Meta could be forced to spin off Instagram and/or WhatsApp.
META Price Action: Meta stock was up 6.5% to $630.80 on Monday, versus a 52-week trading range of $442.65 to $740.89. It is up 5.3% year-to-date in 2025 and 35% over the last year.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/04/45112477/exclusive-if-meta-is-forced-to-divest-instagram-whatsapp-or-facebook-43-pick-this-standout">EXCLUSIVE: If Meta Is Forced To Divest Instagram, WhatsApp, Or Facebook, 43% Pick This Standout</a></li>
</ul>
Photo: Shutterstock

Regulations

Social Media

Politics

Legal

Meta's 'Hail Mary' Before Landmark Antitrust Trial Began: Here's Who The Company Called

Goldman Sachs analyst Matthew Sykes maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Sell and lowers the price target from $7.5 to $6.5.

Goldman Sachs Maintains Sell on 10x Genomics, Lowers Price Target to $6.5

TEVA

Teva Pharmaceuticals shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $21 to $23.

Press Releases

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Korro to Participate in Upcoming Investor Conferences

Management

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

Korro to Present at the TD Cowen 45th Annual Health Care Conference

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

Comments

Korro Bio

Vendite allo scoperto

Korro Bio (NASDAQ:KRRO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO